Printer Friendly

Cancer Genetics' diagnostic genomic tests get included in NIH's Genetic Testing Registry.

M2 PHARMA-August 27, 2014-Cancer Genetics' diagnostic genomic tests get included in NIH's Genetic Testing Registry

(C)2014 M2 COMMUNICATIONS

27 August 2014 - US DNA-based cancer diagnostics company Cancer Genetics Inc (NASDAQ:CGIX) said Wednesday that its diagnostic and prognostic genomic tests had been included in the Genetic Testing Registry (GTR) of the National Institutes of Health (NIH).

GTR is a searchable online database of genetic and genomic tests, providing detailed clinical and scientific information about testing options for physicians and patients.

The company's tests added to the GTR include FHACT, a FISH-based HPV-associated cancer test for cervical cancer that identifies genomic abnormalities related to progression to cancer, UroGenRA-Kidney, a CGH-microarray test that can detect and subtype renal cell carcinoma and may reduce unnecessary nephrectomy for benign tumours, as well as MatBA panel for mature B-cell neoplasms, currently available for chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma and follicular lymphoma.

The tests are CLIA- and New York State-certified and deliver critical data to guide doctors in the clinical management of their patients and guide biopharmaceutcal groups for selection and stratification of clinical study participants.

The addition of the company' tests in the registry broadens access to data about its genomic assays and non-proprietary tests to multiple doctors, oncologists, patients and biopharmaceutical firms, Cancer Genetics noted.

Cancer Genetics' GTR listing includes a total of 40 tests.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 27, 2014
Words:241
Previous Article:Clongen adds new emerging pathogens diagnostic assays to tick, arthropod-borne illness test offering.
Next Article:Genomic Health, Almac join hands on chemotherapy benefit test for breast cancer.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters